+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Beta Lactam and Beta Lactamase Inhibitors Market 2024-2028

  • PDF Icon

    Report

  • 179 Pages
  • March 2024
  • Region: Global
  • TechNavio
  • ID: 5632841
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The beta lactam and beta lactamase inhibitors market is forecasted to grow by USD 10.06 billion during 2023-2028, accelerating at a CAGR of 5.47% during the forecast period. The report on the beta lactam and beta lactamase inhibitors market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising focus on novel drug development, rising antimicrobial resistance, and high disease burden in developing countries.

The beta lactam and beta lactamase inhibitors market is segmented as below:

By Route Of Administration

  • Oral
  • Intravenous
  • Others

By Drug Class

  • Cephalosporins
  • Penicillins
  • Carbapenems
  • Monobactams
  • Combination

By Geographical Landscape

  • North America
  • Europe
  • Asia
  • Rest of World (ROW)
This study identifies the technological advancements in antibiotic discovery as one of the prime reasons driving the beta lactam and beta lactamase inhibitors market growth during the next few years. Also, increased emphasis on antibiotic stewardship and growing emphasis on HAIS will lead to sizable demand in the market.

The report on the beta lactam and beta lactamase inhibitors market covers the following areas:

  • Beta lactam and beta lactamase inhibitors market sizing
  • Beta lactam and beta lactamase inhibitors market forecast
  • Beta lactam and beta lactamase inhibitors market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading beta lactam and beta lactamase inhibitors market vendors that include AbbVie Inc., Alkem Laboratories Ltd., Astellas Pharma Inc., Cipla Ltd., GlaxoSmithKline Plc, Jaiwik Biotech, Lupin Ltd., MedPlus Health Services Ltd., Meiji Holdings Co. Ltd., Merck KGaA, Novartis AG, Numera Life Sciences, Pfizer Inc., Sandoz AG, Sanofi SA, Spero Therapeutics, Taj Pharmaceutical Ltd., Zeelab Laboratories Ltd., Abbott Laboratories, and F. Hoffmann La Roche Ltd.. Also, the beta lactam and beta lactamase inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1 Executive Summary
1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Global Market Characteristics
Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
Exhibit 05: Executive Summary - Chart on Market Segmentation by Route of Administration
Exhibit 06: Executive Summary - Chart on Market Segmentation by Drug Class
Exhibit 07: Executive Summary - Chart on Incremental Growth
Exhibit 08: Executive Summary - Data Table on Incremental Growth
Exhibit 09: Executive Summary - Chart on Vendor Market Positioning
2 Market Landscape
2.1 Market ecosystem
Exhibit 10: Parent market
Exhibit 11: Market Characteristics
3 Market Sizing
3.1 Market definition
Exhibit 12: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 13: Market segments
3.3 Market size 2023
3.4 Market outlook: Forecast for 2023-2028
Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ billion)
Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ billion)
Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
4 Historic Market Size
4.1 Global beta lactam and beta lactamase inhibitors market 2018 - 2022
Exhibit 18: Historic Market Size - Data Table on global beta lactam and beta lactamase inhibitors market 2018 - 2022 ($ billion)
4.2 Route of Administration Segment Analysis 2018 - 2022
Exhibit 19: Historic Market Size - Route of Administration Segment 2018 - 2022 ($ billion)
4.3 Drug Class Segment Analysis 2018 - 2022
Exhibit 20: Historic Market Size - Drug Class Segment 2018 - 2022 ($ billion)
4.4 Geography Segment Analysis 2018 - 2022
Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ billion)
4.5 Country Segment Analysis 2018 - 2022
Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ billion)
5 Five Forces Analysis
5.1 Five forces summary
Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
5.2 Bargaining power of buyers
Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
5.3 Bargaining power of suppliers
Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
5.4 Threat of new entrants
Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028
5.5 Threat of substitutes
Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028
5.6 Threat of rivalry
Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028
5.7 Market condition
Exhibit 29: Chart on Market condition - Five forces 2023 and 2028
6 Market Segmentation by Route of Administration
6.1 Market segments
Exhibit 30: Chart on Route of Administration - Market share 2023-2028 (%)
Exhibit 31: Data Table on Route of Administration - Market share 2023-2028 (%)
6.2 Comparison by Route of Administration
Exhibit 32: Chart on Comparison by Route of Administration
Exhibit 33: Data Table on Comparison by Route of Administration
6.3 Oral - Market size and forecast 2023-2028
Exhibit 34: Chart on Oral - Market size and forecast 2023-2028 ($ billion)
Exhibit 35: Data Table on Oral - Market size and forecast 2023-2028 ($ billion)
Exhibit 36: Chart on Oral - Year-over-year growth 2023-2028 (%)
Exhibit 37: Data Table on Oral - Year-over-year growth 2023-2028 (%)
6.4 Intravenous - Market size and forecast 2023-2028
Exhibit 38: Chart on Intravenous - Market size and forecast 2023-2028 ($ billion)
Exhibit 39: Data Table on Intravenous - Market size and forecast 2023-2028 ($ billion)
Exhibit 40: Chart on Intravenous - Year-over-year growth 2023-2028 (%)
Exhibit 41: Data Table on Intravenous - Year-over-year growth 2023-2028 (%)
6.5 Others - Market size and forecast 2023-2028
Exhibit 42: Chart on Others - Market size and forecast 2023-2028 ($ billion)
Exhibit 43: Data Table on Others - Market size and forecast 2023-2028 ($ billion)
Exhibit 44: Chart on Others - Year-over-year growth 2023-2028 (%)
Exhibit 45: Data Table on Others - Year-over-year growth 2023-2028 (%)
6.6 Market opportunity by Route of Administration
Exhibit 46: Market opportunity by Route of Administration ($ billion)
Exhibit 47: Data Table on Market opportunity by Route of Administration ($ billion)
7 Market Segmentation by Drug Class
7.1 Market segments
Exhibit 48: Chart on Drug Class - Market share 2023-2028 (%)
Exhibit 49: Data Table on Drug Class - Market share 2023-2028 (%)
7.2 Comparison by Drug Class
Exhibit 50: Chart on Comparison by Drug Class
Exhibit 51: Data Table on Comparison by Drug Class
7.3 Cephalosporins - Market size and forecast 2023-2028
Exhibit 52: Chart on Cephalosporins - Market size and forecast 2023-2028 ($ billion)
Exhibit 53: Data Table on Cephalosporins - Market size and forecast 2023-2028 ($ billion)
Exhibit 54: Chart on Cephalosporins - Year-over-year growth 2023-2028 (%)
Exhibit 55: Data Table on Cephalosporins - Year-over-year growth 2023-2028 (%)
7.4 Penicillins - Market size and forecast 2023-2028
Exhibit 56: Chart on Penicillins - Market size and forecast 2023-2028 ($ billion)
Exhibit 57: Data Table on Penicillins - Market size and forecast 2023-2028 ($ billion)
Exhibit 58: Chart on Penicillins - Year-over-year growth 2023-2028 (%)
Exhibit 59: Data Table on Penicillins - Year-over-year growth 2023-2028 (%)
7.5 Carbapenems - Market size and forecast 2023-2028
Exhibit 60: Chart on Carbapenems - Market size and forecast 2023-2028 ($ billion)
Exhibit 61: Data Table on Carbapenems - Market size and forecast 2023-2028 ($ billion)
Exhibit 62: Chart on Carbapenems - Year-over-year growth 2023-2028 (%)
Exhibit 63: Data Table on Carbapenems - Year-over-year growth 2023-2028 (%)
7.6 Monobactams - Market size and forecast 2023-2028
Exhibit 64: Chart on Monobactams - Market size and forecast 2023-2028 ($ billion)
Exhibit 65: Data Table on Monobactams - Market size and forecast 2023-2028 ($ billion)
Exhibit 66: Chart on Monobactams - Year-over-year growth 2023-2028 (%)
Exhibit 67: Data Table on Monobactams - Year-over-year growth 2023-2028 (%)
7.7 Combination - Market size and forecast 2023-2028
Exhibit 68: Chart on Combination - Market size and forecast 2023-2028 ($ billion)
Exhibit 69: Data Table on Combination - Market size and forecast 2023-2028 ($ billion)
Exhibit 70: Chart on Combination - Year-over-year growth 2023-2028 (%)
Exhibit 71: Data Table on Combination - Year-over-year growth 2023-2028 (%)
7.8 Market opportunity by Drug Class
Exhibit 72: Market opportunity by Drug Class ($ billion)
Exhibit 73: Data Table on Market opportunity by Drug Class ($ billion)
8 Customer Landscape
8.1 Customer landscape overview
Exhibit 74: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
9 Geographic Landscape
9.1 Geographic segmentation
Exhibit 75: Chart on Market share By Geographical Landscape 2023-2028 (%)
Exhibit 76: Data Table on Market share By Geographical Landscape 2023-2028 (%)
9.2 Geographic comparison
Exhibit 77: Chart on Geographic comparison
Exhibit 78: Data Table on Geographic comparison
9.3 North America - Market size and forecast 2023-2028
Exhibit 79: Chart on North America - Market size and forecast 2023-2028 ($ billion)
Exhibit 80: Data Table on North America - Market size and forecast 2023-2028 ($ billion)
Exhibit 81: Chart on North America - Year-over-year growth 2023-2028 (%)
Exhibit 82: Data Table on North America - Year-over-year growth 2023-2028 (%)
9.4 Europe - Market size and forecast 2023-2028
Exhibit 83: Chart on Europe - Market size and forecast 2023-2028 ($ billion)
Exhibit 84: Data Table on Europe - Market size and forecast 2023-2028 ($ billion)
Exhibit 85: Chart on Europe - Year-over-year growth 2023-2028 (%)
Exhibit 86: Data Table on Europe - Year-over-year growth 2023-2028 (%)
9.5 Asia - Market size and forecast 2023-2028
Exhibit 87: Chart on Asia - Market size and forecast 2023-2028 ($ billion)
Exhibit 88: Data Table on Asia - Market size and forecast 2023-2028 ($ billion)
Exhibit 89: Chart on Asia - Year-over-year growth 2023-2028 (%)
Exhibit 90: Data Table on Asia - Year-over-year growth 2023-2028 (%)
9.6 Rest of World (ROW) - Market size and forecast 2023-2028
Exhibit 91: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
Exhibit 92: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
Exhibit 93: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibit 94: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
9.7 US - Market size and forecast 2023-2028
Exhibit 95: Chart on US - Market size and forecast 2023-2028 ($ billion)
Exhibit 96: Data Table on US - Market size and forecast 2023-2028 ($ billion)
Exhibit 97: Chart on US - Year-over-year growth 2023-2028 (%)
Exhibit 98: Data Table on US - Year-over-year growth 2023-2028 (%)
9.8 China - Market size and forecast 2023-2028
Exhibit 99: Chart on China - Market size and forecast 2023-2028 ($ billion)
Exhibit 100: Data Table on China - Market size and forecast 2023-2028 ($ billion)
Exhibit 101: Chart on China - Year-over-year growth 2023-2028 (%)
Exhibit 102: Data Table on China - Year-over-year growth 2023-2028 (%)
9.9 Germany - Market size and forecast 2023-2028
Exhibit 103: Chart on Germany - Market size and forecast 2023-2028 ($ billion)
Exhibit 104: Data Table on Germany - Market size and forecast 2023-2028 ($ billion)
Exhibit 105: Chart on Germany - Year-over-year growth 2023-2028 (%)
Exhibit 106: Data Table on Germany - Year-over-year growth 2023-2028 (%)
9.10 India - Market size and forecast 2023-2028
Exhibit 107: Chart on India - Market size and forecast 2023-2028 ($ billion)
Exhibit 108: Data Table on India - Market size and forecast 2023-2028 ($ billion)
Exhibit 109: Chart on India - Year-over-year growth 2023-2028 (%)
Exhibit 110: Data Table on India - Year-over-year growth 2023-2028 (%)
9.11 UK - Market size and forecast 2023-2028
Exhibit 111: Chart on UK - Market size and forecast 2023-2028 ($ billion)
Exhibit 112: Data Table on UK - Market size and forecast 2023-2028 ($ billion)
Exhibit 113: Chart on UK - Year-over-year growth 2023-2028 (%)
Exhibit 114: Data Table on UK - Year-over-year growth 2023-2028 (%)
9.12 Market opportunity By Geographical Landscape
Exhibit 115: Market opportunity By Geographical Landscape ($ billion)
Exhibit 116: Data Tables on Market opportunity By Geographical Landscape ($ billion)
10 Drivers, Challenges, and Trends
10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
Exhibit 117: Impact of drivers and challenges in 2023 and 2028
10.4 Market trends
11 Vendor Landscape
11.1 Overview
11.2 Vendor landscape
Exhibit 118: Overview on Criticality of inputs and Factors of differentiation
11.3 Landscape disruption
Exhibit 119: Overview on factors of disruption
11.4 Industry risks
Exhibit 120: Impact of key risks on business
12 Vendor Analysis
12.1 Vendors covered
Exhibit 121: Vendors covered
12.2 Market positioning of vendors
Exhibit 122: Matrix on vendor position and classification
12.3 Abbott Laboratories
Exhibit 123: Abbott Laboratories - Overview
Exhibit 124: Abbott Laboratories - Business segments
Exhibit 125: Abbott Laboratories - Key offerings
Exhibit 126: Abbott Laboratories - Segment focus
12.4 AbbVie Inc.
Exhibit 127: AbbVie Inc. - Overview
Exhibit 128: AbbVie Inc. - Product / Service
Exhibit 129: AbbVie Inc. - Key news
Exhibit 130: AbbVie Inc. - Key offerings
12.5 Alkem Laboratories Ltd.
Exhibit 131: Alkem Laboratories Ltd. - Overview
Exhibit 132: Alkem Laboratories Ltd. - Business segments
Exhibit 133: Alkem Laboratories Ltd. - Key news
Exhibit 134: Alkem Laboratories Ltd. - Key offerings
Exhibit 135: Alkem Laboratories Ltd. - Segment focus
12.6 Astellas Pharma Inc.
Exhibit 136: Astellas Pharma Inc. - Overview
Exhibit 137: Astellas Pharma Inc. - Product / Service
Exhibit 138: Astellas Pharma Inc. - Key news
Exhibit 139: Astellas Pharma Inc. - Key offerings
12.7 Cipla Ltd.
Exhibit 140: Cipla Ltd. - Overview
Exhibit 141: Cipla Ltd. - Business segments
Exhibit 142: Cipla Ltd. - Key news
Exhibit 143: Cipla Ltd. - Key offerings
Exhibit 144: Cipla Ltd. - Segment focus
12.8 F. Hoffmann La Roche Ltd.
Exhibit 145: F. Hoffmann La Roche Ltd. - Overview
Exhibit 146: F. Hoffmann La Roche Ltd. - Business segments
Exhibit 147: F. Hoffmann La Roche Ltd. - Key news
Exhibit 148: F. Hoffmann La Roche Ltd. - Key offerings
Exhibit 149: F. Hoffmann La Roche Ltd. - Segment focus
12.9 GlaxoSmithKline Plc
Exhibit 150: GlaxoSmithKline Plc - Overview
Exhibit 151: GlaxoSmithKline Plc - Business segments
Exhibit 152: GlaxoSmithKline Plc - Key news
Exhibit 153: GlaxoSmithKline Plc - Key offerings
Exhibit 154: GlaxoSmithKline Plc - Segment focus
12.10 MedPlus Health Services Ltd.
Exhibit 155: MedPlus Health Services Ltd. - Overview
Exhibit 156: MedPlus Health Services Ltd. - Product / Service
Exhibit 157: MedPlus Health Services Ltd. - Key offerings
12.11 Meiji Holdings Co. Ltd.
Exhibit 158: Meiji Holdings Co. Ltd. - Overview
Exhibit 159: Meiji Holdings Co. Ltd. - Business segments
Exhibit 160: Meiji Holdings Co. Ltd. - Key news
Exhibit 161: Meiji Holdings Co. Ltd. - Key offerings
Exhibit 162: Meiji Holdings Co. Ltd. - Segment focus
12.12 Merck KGaA
Exhibit 163: Merck KGaA - Overview
Exhibit 164: Merck KGaA - Business segments
Exhibit 165: Merck KGaA - Key news
Exhibit 166: Merck KGaA - Key offerings
Exhibit 167: Merck KGaA - Segment focus
12.13 Novartis AG
Exhibit 168: Novartis AG - Overview
Exhibit 169: Novartis AG - Business segments
Exhibit 170: Novartis AG - Key news
Exhibit 171: Novartis AG - Key offerings
Exhibit 172: Novartis AG - Segment focus
12.14 Pfizer Inc.
Exhibit 173: Pfizer Inc. - Overview
Exhibit 174: Pfizer Inc. - Product / Service
Exhibit 175: Pfizer Inc. - Key news
Exhibit 176: Pfizer Inc. - Key offerings
12.15 Sandoz AG
Exhibit 177: Sandoz AG - Overview
Exhibit 178: Sandoz AG - Product / Service
Exhibit 179: Sandoz AG - Key news
Exhibit 180: Sandoz AG - Key offerings
12.16 Sanofi SA
Exhibit 181: Sanofi SA - Overview
Exhibit 182: Sanofi SA - Business segments
Exhibit 183: Sanofi SA - Key news
Exhibit 184: Sanofi SA - Key offerings
Exhibit 185: Sanofi SA - Segment focus
12.17 Spero Therapeutics
Exhibit 186: Spero Therapeutics - Overview
Exhibit 187: Spero Therapeutics - Product / Service
Exhibit 188: Spero Therapeutics - Key offerings
13 Appendix
13.1 Scope of the report
13.2 Inclusions and exclusions checklist
Exhibit 189: Inclusions checklist
Exhibit 190: Exclusions checklist
13.3 Currency conversion rates for US$
Exhibit 191: Currency conversion rates for US$
13.4 Research methodology
Exhibit 192: Research methodology
Exhibit 193: Validation techniques employed for market sizing
Exhibit 194: Information sources
13.5 List of abbreviations
Exhibit 195: List of abbreviations
List of Exhibits
Exhibits 1: Executive Summary - Chart on Market Overview
Exhibits 2: Executive Summary - Data Table on Market Overview
Exhibits 3: Executive Summary - Chart on Global Market Characteristics
Exhibits 4: Executive Summary - Chart on Market By Geographical Landscape
Exhibits 5: Executive Summary - Chart on Market Segmentation by Route of Administration
Exhibits 6: Executive Summary - Chart on Market Segmentation by Drug Class
Exhibits 7: Executive Summary - Chart on Incremental Growth
Exhibits 8: Executive Summary - Data Table on Incremental Growth
Exhibits 9: Executive Summary - Chart on Vendor Market Positioning
Exhibits 10: Parent market
Exhibits 11: Market Characteristics
Exhibits 12: Offerings of vendors included in the market definition
Exhibits 13: Market segments
Exhibits 14: Chart on Global - Market size and forecast 2023-2028 ($ billion)
Exhibits 15: Data Table on Global - Market size and forecast 2023-2028 ($ billion)
Exhibits 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
Exhibits 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
Exhibits 18: Historic Market Size - Data Table on global beta lactam and beta lactamase inhibitors market 2018 - 2022 ($ billion)
Exhibits 19: Historic Market Size - Route of Administration Segment 2018 - 2022 ($ billion)
Exhibits 20: Historic Market Size - Drug Class Segment 2018 - 2022 ($ billion)
Exhibits 21: Historic Market Size - Geography Segment 2018 - 2022 ($ billion)
Exhibits 22: Historic Market Size - Country Segment 2018 - 2022 ($ billion)
Exhibits 23: Five forces analysis - Comparison between 2023 and 2028
Exhibits 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
Exhibits 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
Exhibits 26: Threat of new entrants - Impact of key factors in 2023 and 2028
Exhibits 27: Threat of substitutes - Impact of key factors in 2023 and 2028
Exhibits 28: Threat of rivalry - Impact of key factors in 2023 and 2028
Exhibits 29: Chart on Market condition - Five forces 2023 and 2028
Exhibits 30: Chart on Route of Administration - Market share 2023-2028 (%)
Exhibits 31: Data Table on Route of Administration - Market share 2023-2028 (%)
Exhibits 32: Chart on Comparison by Route of Administration
Exhibits 33: Data Table on Comparison by Route of Administration
Exhibits 34: Chart on Oral - Market size and forecast 2023-2028 ($ billion)
Exhibits 35: Data Table on Oral - Market size and forecast 2023-2028 ($ billion)
Exhibits 36: Chart on Oral - Year-over-year growth 2023-2028 (%)
Exhibits 37: Data Table on Oral - Year-over-year growth 2023-2028 (%)
Exhibits 38: Chart on Intravenous - Market size and forecast 2023-2028 ($ billion)
Exhibits 39: Data Table on Intravenous - Market size and forecast 2023-2028 ($ billion)
Exhibits 40: Chart on Intravenous - Year-over-year growth 2023-2028 (%)
Exhibits 41: Data Table on Intravenous - Year-over-year growth 2023-2028 (%)
Exhibits 42: Chart on Others - Market size and forecast 2023-2028 ($ billion)
Exhibits 43: Data Table on Others - Market size and forecast 2023-2028 ($ billion)
Exhibits 44: Chart on Others - Year-over-year growth 2023-2028 (%)
Exhibits 45: Data Table on Others - Year-over-year growth 2023-2028 (%)
Exhibits 46: Market opportunity by Route of Administration ($ billion)
Exhibits 47: Data Table on Market opportunity by Route of Administration ($ billion)
Exhibits 48: Chart on Drug Class - Market share 2023-2028 (%)
Exhibits 49: Data Table on Drug Class - Market share 2023-2028 (%)
Exhibits 50: Chart on Comparison by Drug Class
Exhibits 51: Data Table on Comparison by Drug Class
Exhibits 52: Chart on Cephalosporins - Market size and forecast 2023-2028 ($ billion)
Exhibits 53: Data Table on Cephalosporins - Market size and forecast 2023-2028 ($ billion)
Exhibits 54: Chart on Cephalosporins - Year-over-year growth 2023-2028 (%)
Exhibits 55: Data Table on Cephalosporins - Year-over-year growth 2023-2028 (%)
Exhibits 56: Chart on Penicillins - Market size and forecast 2023-2028 ($ billion)
Exhibits 57: Data Table on Penicillins - Market size and forecast 2023-2028 ($ billion)
Exhibits 58: Chart on Penicillins - Year-over-year growth 2023-2028 (%)
Exhibits 59: Data Table on Penicillins - Year-over-year growth 2023-2028 (%)
Exhibits 60: Chart on Carbapenems - Market size and forecast 2023-2028 ($ billion)
Exhibits 61: Data Table on Carbapenems - Market size and forecast 2023-2028 ($ billion)
Exhibits 62: Chart on Carbapenems - Year-over-year growth 2023-2028 (%)
Exhibits 63: Data Table on Carbapenems - Year-over-year growth 2023-2028 (%)
Exhibits 64: Chart on Monobactams - Market size and forecast 2023-2028 ($ billion)
Exhibits 65: Data Table on Monobactams - Market size and forecast 2023-2028 ($ billion)
Exhibits 66: Chart on Monobactams - Year-over-year growth 2023-2028 (%)
Exhibits 67: Data Table on Monobactams - Year-over-year growth 2023-2028 (%)
Exhibits 68: Chart on Combination - Market size and forecast 2023-2028 ($ billion)
Exhibits 69: Data Table on Combination - Market size and forecast 2023-2028 ($ billion)
Exhibits 70: Chart on Combination - Year-over-year growth 2023-2028 (%)
Exhibits 71: Data Table on Combination - Year-over-year growth 2023-2028 (%)
Exhibits 72: Market opportunity by Drug Class ($ billion)
Exhibits 73: Data Table on Market opportunity by Drug Class ($ billion)
Exhibits 74: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits 75: Chart on Market share By Geographical Landscape 2023-2028 (%)
Exhibits 76: Data Table on Market share By Geographical Landscape 2023-2028 (%)
Exhibits 77: Chart on Geographic comparison
Exhibits 78: Data Table on Geographic comparison
Exhibits 79: Chart on North America - Market size and forecast 2023-2028 ($ billion)
Exhibits 80: Data Table on North America - Market size and forecast 2023-2028 ($ billion)
Exhibits 81: Chart on North America - Year-over-year growth 2023-2028 (%)
Exhibits 82: Data Table on North America - Year-over-year growth 2023-2028 (%)
Exhibits 83: Chart on Europe - Market size and forecast 2023-2028 ($ billion)
Exhibits 84: Data Table on Europe - Market size and forecast 2023-2028 ($ billion)
Exhibits 85: Chart on Europe - Year-over-year growth 2023-2028 (%)
Exhibits 86: Data Table on Europe - Year-over-year growth 2023-2028 (%)
Exhibits 87: Chart on Asia - Market size and forecast 2023-2028 ($ billion)
Exhibits 88: Data Table on Asia - Market size and forecast 2023-2028 ($ billion)
Exhibits 89: Chart on Asia - Year-over-year growth 2023-2028 (%)
Exhibits 90: Data Table on Asia - Year-over-year growth 2023-2028 (%)
Exhibits 91: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
Exhibits 92: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
Exhibits 93: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibits 94: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibits 95: Chart on US - Market size and forecast 2023-2028 ($ billion)
Exhibits 96: Data Table on US - Market size and forecast 2023-2028 ($ billion)
Exhibits 97: Chart on US - Year-over-year growth 2023-2028 (%)
Exhibits 98: Data Table on US - Year-over-year growth 2023-2028 (%)
Exhibits 99: Chart on China - Market size and forecast 2023-2028 ($ billion)
Exhibits 100: Data Table on China - Market size and forecast 2023-2028 ($ billion)
Exhibits 101: Chart on China - Year-over-year growth 2023-2028 (%)
Exhibits 102: Data Table on China - Year-over-year growth 2023-2028 (%)
Exhibits 103: Chart on Germany - Market size and forecast 2023-2028 ($ billion)
Exhibits 104: Data Table on Germany - Market size and forecast 2023-2028 ($ billion)
Exhibits 105: Chart on Germany - Year-over-year growth 2023-2028 (%)
Exhibits 106: Data Table on Germany - Year-over-year growth 2023-2028 (%)
Exhibits 107: Chart on India - Market size and forecast 2023-2028 ($ billion)
Exhibits 108: Data Table on India - Market size and forecast 2023-2028 ($ billion)
Exhibits 109: Chart on India - Year-over-year growth 2023-2028 (%)
Exhibits 110: Data Table on India - Year-over-year growth 2023-2028 (%)
Exhibits 111: Chart on UK - Market size and forecast 2023-2028 ($ billion)
Exhibits 112: Data Table on UK - Market size and forecast 2023-2028 ($ billion)
Exhibits 113: Chart on UK - Year-over-year growth 2023-2028 (%)
Exhibits 114: Data Table on UK - Year-over-year growth 2023-2028 (%)
Exhibits 115: Market opportunity By Geographical Landscape ($ billion)
Exhibits 116: Data Tables on Market opportunity By Geographical Landscape ($ billion)
Exhibits 117: Impact of drivers and challenges in 2023 and 2028
Exhibits 118: Overview on Criticality of inputs and Factors of differentiation
Exhibits 119: Overview on factors of disruption
Exhibits 120: Impact of key risks on business
Exhibits 121: Vendors covered
Exhibits 122: Matrix on vendor position and classification
Exhibits 123: Abbott Laboratories - Overview
Exhibits 124: Abbott Laboratories - Business segments
Exhibits 125: Abbott Laboratories - Key offerings
Exhibits 126: Abbott Laboratories - Segment focus
Exhibits 127: AbbVie Inc. - Overview
Exhibits 128: AbbVie Inc. - Product / Service
Exhibits 129: AbbVie Inc. - Key news
Exhibits 130: AbbVie Inc. - Key offerings
Exhibits 131: Alkem Laboratories Ltd. - Overview
Exhibits 132: Alkem Laboratories Ltd. - Business segments
Exhibits 133: Alkem Laboratories Ltd. - Key news
Exhibits 134: Alkem Laboratories Ltd. - Key offerings
Exhibits 135: Alkem Laboratories Ltd. - Segment focus
Exhibits 136: Astellas Pharma Inc. - Overview
Exhibits 137: Astellas Pharma Inc. - Product / Service
Exhibits 138: Astellas Pharma Inc. - Key news
Exhibits 139: Astellas Pharma Inc. - Key offerings
Exhibits 140: Cipla Ltd. - Overview
Exhibits 141: Cipla Ltd. - Business segments
Exhibits 142: Cipla Ltd. - Key news
Exhibits 143: Cipla Ltd. - Key offerings
Exhibits 144: Cipla Ltd. - Segment focus
Exhibits 145: F. Hoffmann La Roche Ltd. - Overview
Exhibits 146: F. Hoffmann La Roche Ltd. - Business segments
Exhibits 147: F. Hoffmann La Roche Ltd. - Key news
Exhibits 148: F. Hoffmann La Roche Ltd. - Key offerings
Exhibits 149: F. Hoffmann La Roche Ltd. - Segment focus
Exhibits 150: GlaxoSmithKline Plc - Overview
Exhibits 151: GlaxoSmithKline Plc - Business segments
Exhibits 152: GlaxoSmithKline Plc - Key news
Exhibits 153: GlaxoSmithKline Plc - Key offerings
Exhibits 154: GlaxoSmithKline Plc - Segment focus
Exhibits 155: MedPlus Health Services Ltd. - Overview
Exhibits 156: MedPlus Health Services Ltd. - Product / Service
Exhibits 157: MedPlus Health Services Ltd. - Key offerings
Exhibits 158: Meiji Holdings Co. Ltd. - Overview
Exhibits 159: Meiji Holdings Co. Ltd. - Business segments
Exhibits 160: Meiji Holdings Co. Ltd. - Key news
Exhibits 161: Meiji Holdings Co. Ltd. - Key offerings
Exhibits 162: Meiji Holdings Co. Ltd. - Segment focus
Exhibits 163: Merck KGaA - Overview
Exhibits 164: Merck KGaA - Business segments
Exhibits 165: Merck KGaA - Key news
Exhibits 166: Merck KGaA - Key offerings
Exhibits 167: Merck KGaA - Segment focus
Exhibits 168: Novartis AG - Overview
Exhibits 169: Novartis AG - Business segments
Exhibits 170: Novartis AG - Key news
Exhibits 171: Novartis AG - Key offerings
Exhibits 172: Novartis AG - Segment focus
Exhibits 173: Pfizer Inc. - Overview
Exhibits 174: Pfizer Inc. - Product / Service
Exhibits 175: Pfizer Inc. - Key news
Exhibits 176: Pfizer Inc. - Key offerings
Exhibits 177: Sandoz AG - Overview
Exhibits 178: Sandoz AG - Product / Service
Exhibits 179: Sandoz AG - Key news
Exhibits 180: Sandoz AG - Key offerings
Exhibits 181: Sanofi SA - Overview
Exhibits 182: Sanofi SA - Business segments
Exhibits 183: Sanofi SA - Key news
Exhibits 184: Sanofi SA - Key offerings
Exhibits 185: Sanofi SA - Segment focus
Exhibits 186: Spero Therapeutics - Overview
Exhibits 187: Spero Therapeutics - Product / Service
Exhibits 188: Spero Therapeutics - Key offerings
Exhibits 189: Inclusions checklist
Exhibits 190: Exclusions checklist
Exhibits 191: Currency conversion rates for US$
Exhibits 192: Research methodology
Exhibits 193: Validation techniques employed for market sizing
Exhibits 194: Information sources
Exhibits 195: List of abbreviations

Executive Summary

The following companies are recognized as the key players in the global beta lactam and beta lactamase inhibitors market: AbbVie Inc., Alkem Laboratories Ltd., Astellas Pharma Inc., Cipla Ltd., GlaxoSmithKline Plc, Jaiwik Biotech, Lupin Ltd., MedPlus Health Services Ltd., Meiji Holdings Co. Ltd., Merck KGaA, Novartis AG, Numera Life Sciences, Pfizer Inc., Sandoz AG, Sanofi SA, Spero Therapeutics, Taj Pharmaceutical Ltd., Zeelab Laboratories Ltd., Abbott Laboratories, and F. Hoffmann La Roche Ltd..

Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is technological advancements in antibiotic discovery."

According to the report, one of the major drivers for this market is the rising focus on novel drug development.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • AbbVie Inc.
  • Alkem Laboratories Ltd.
  • Astellas Pharma Inc.
  • Cipla Ltd.
  • GlaxoSmithKline Plc
  • Jaiwik Biotech
  • Lupin Ltd.
  • MedPlus Health Services Ltd.
  • Meiji Holdings Co. Ltd.
  • Merck KGaA
  • Novartis AG
  • Numera Life Sciences
  • Pfizer Inc.
  • Sandoz AG
  • Sanofi SA
  • Spero Therapeutics
  • Taj Pharmaceutical Ltd.
  • Zeelab Laboratories Ltd.
  • Abbott Laboratories
  • F. Hoffmann La Roche Ltd.